Myeloma

Top Story

Autologous HSCT underused despite survival benefits for newly diagnosed multiple myeloma

Autologous HSCT underused despite survival benefits for newly diagnosed multiple myeloma
September 10, 2018

Research updates for Blood Cancer Awareness Month

September 10, 2018
The Leukemia & Lymphoma Society has deemed September Blood Cancer Awareness Month. Blood cancers are the third leading cause of cancer deaths in the U.S., with a…
Feature

Harvard initiative aims to determine why certain patients are ’exceptional responders’

September 6, 2018
A Harvard Medical School project will mine multiple data sources to try to determine why some patients are more likely to have exceptional responses to cancer…

CAR T-cell therapy appears safe for multiple myeloma

September 6, 2018
The chimeric antigen receptor T-cell therapy P-BCMA-101 appeared safe among patients with relapsed/refractory multiple myeloma, according to the agent’s…
More Headlines »
CME CPE CNE

Decisions, Decisions: Differentiating Checkpoint Inhibitors for Bladder Cancer

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

Lung cancer is a leading cause of cancer death worldwide. The American Cancer Society estimates that there will be…
More »
Video
Meeting News

VIDEO: Takeda executive highlights research efforts in lung cancer, myeloma, myelodysplastic syndrome

June 19, 2018
More »
Resource Centers
Immuno-Oncology Resource Center

Immuno-Oncology Resource Center

CME ABIM MOC

Ace the Case: A 52-Year-Old Man with an Asymptomatic Neck Mass

There is no commercial support for this activity.

This educational activity will discuss the approach to diagnosis and management of a 52-year-old man who presents with…
More »